Researchers tracked more than 2,800 patients with venous thromboembolism and found that treatment with the anticoagulant dabigatran was associated with a lower risk of major bleeding compared with warfarin. The study appeared in the New England Journal of Medicine.
Study: Dabigatran lowers major bleeding risk in VTE patients
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Vice President of Finance||
Urban Health Plan, Inc.
|Director of Payor/Provider Contracting||
U.S. Medical Management